Zdenek brings sharp strategic insight, strong investment acumen, and a deep understanding of healthcare and finance to identify and support high-potential startups. His strengths lie in driving operational excellence, scaling businesses, and navigating complex transactions.

Marios combines deep financial expertise with a passion for innovation to drive investment in disruptive, high-growth startups. With a focus on deal structuring, strategic guidance, and hands-on mentoring, he empowers founders to scale effectively while building long-term value across the portfolio.

Milan brings a unique blend of technical expertise and entrepreneurial vision. He has been instrumental in scaling STAPRO into a leading healthcare IT provider in Central and Eastern Europe, while actively supporting breakthrough ventures that are transforming patient care.

Zdenek combines strategic vision with deep operational expertise, playing a central role in building STAPRO into a leading healthcare IT provider in CEE. He also spearheads the Group’s investments in high-impact ventures that are pushing the boundaries of innovation in diagnostics and patient care.

Leos offers a strategic edge in evaluating digital health and AI-driven opportunities, contributing critical insight to the identification of high-growth ventures with real-world impact.

Vojtech leads the development of university talent networks, playing a pivotal role in identifying and nurturing innovative, high-potential startups.

Martin's expertise in due diligence and financial structuring is critical for evaluating investment opportunities.

Prof. Zima is a professor of medical chemistry and biochemistry and Head of the Institute of Medical Biochemistry and Laboratory Medicine at the First Faculty of Medicine, Charles University in Prague. He previously served as Dean and later as Rector of Charles University. A leading expert in medical chemistry, biochemistry, and biotech-related research.

Martina Schäfer Benešová is a nuclear chemist and research team leader at the German Cancer Research Center, (DKFZ), Heidelberg, specializing in radiopharmaceuticals for targeted oncology. She leads the Translational Radiotheranostics Group, advancing alpha-emitting therapeutics and precision imaging in collaboration with Bayer AG.

Dimitrios provides crucial insights on tech feasibility and growth, directly shaping investment strategies and guiding founders towards scalable success.

Martin provides critical scientific insight that supports the evaluation of healthcare-related investment opportunities in terms of real-world medical relevance and long-term patient impact.

With a strong background in transaction law, Jan provides invaluable guidance on complex legal matters, ensuring strategic and compliant decision-making.

Dominik’s investment opportunities pipeline analysis enables the identification of high-potential startups.

Zdenek brings sharp strategic insight, strong investment acumen, and a deep understanding of healthcare and finance to identify and support high-potential startups. His strengths lie in driving operational excellence, scaling businesses, and navigating complex transactions.

Marios combines deep financial expertise with a passion for innovation to drive investment in disruptive, high-growth startups. With a focus on deal structuring, strategic guidance, and hands-on mentoring, he empowers founders to scale effectively while building long-term value across the portfolio.

Milan brings a unique blend of technical expertise and entrepreneurial vision. He has been instrumental in scaling STAPRO into a leading healthcare IT provider in Central and Eastern Europe, while actively supporting breakthrough ventures that are transforming patient care.

Zdenek combines strategic vision with deep operational expertise, playing a central role in building STAPRO into a leading healthcare IT provider in CEE. He also spearheads the Group’s investments in high-impact ventures that are pushing the boundaries of innovation in diagnostics and patient care.

Leos offers a strategic edge in evaluating digital health and AI-driven opportunities, contributing critical insight to the identification of high-growth ventures with real-world impact.

Vojtech leads the development of university talent networks, playing a pivotal role in identifying and nurturing innovative, high-potential startups.

Martin's expertise in due diligence and financial structuring is critical for evaluating investment opportunities.

Prof. Zima is a professor of medical chemistry and biochemistry and Head of the Institute of Medical Biochemistry and Laboratory Medicine at the First Faculty of Medicine, Charles University in Prague. He previously served as Dean and later as Rector of Charles University. A leading expert in medical chemistry, biochemistry, and biotech-related research.

Martina Schäfer Benešová is a nuclear chemist and research team leader at the German Cancer Research Center, (DKFZ), Heidelberg, specializing in radiopharmaceuticals for targeted oncology. She leads the Translational Radiotheranostics Group, advancing alpha-emitting therapeutics and precision imaging in collaboration with Bayer AG.

Dimitrios provides crucial insights on tech feasibility and growth, directly shaping investment strategies and guiding founders towards scalable success.

Martin provides critical scientific insight that supports the evaluation of healthcare-related investment opportunities in terms of real-world medical relevance and long-term patient impact.

With a strong background in transaction law, Jan provides invaluable guidance on complex legal matters, ensuring strategic and compliant decision-making.

Dominik’s investment opportunities pipeline analysis enables the identification of high-potential startups.